A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

Trial ID # NCT02608684
Phase II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Cisplatin, Gemcitabine, Pembrolizumab
Eligible Participant

Platinum resistant or refractory ovarian cancer

Patients Enrolled

21; 20 HGS, 1 clear cell, median 2 prior therapies (1-5), 47.6% prior bevacizumab

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

ORR, DCR, DoR, PFS, evaluated per RECIST

Efficacy

ORR: 61.1% (1CR, 10PR, n=18)
DCR: 88.9% (1CR, 10PR, 5SD, n=18)
DoR: 4.9 months
PFS: 6.2 months
Four patients received palliative radiation treatment. After receiving palliative radiation during pembrolizumab maintenance, one patient with recurrent clear cell ovarian cancer had reversal and normalization of CA125 trend, RECIST response improved from SD to PR, and response appears to be durable (completed 2 years of therapy and remains without disease 11 months after).

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: fatigue 14.2%

Conclusion

Adding pembrolizumab to cisplatin+gemcitabine and continuing as single-agent maintenance treatment results in promising response rates

Reference

Walsh CS et al. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoSOne (2021) 16(6):e0252665
https://pubmed.ncbi.nlm.nih.gov/34081738/

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.